NASDAQ:CGEN - Compugen Stock Price, Forecast & News

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Monday, November, 11th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.01. View Compugen's Earnings History.

Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Compugen.

2 equities research analysts have issued 12-month target prices for Compugen's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Compugen's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price. View Analyst Price Targets for Compugen.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

Media coverage about CGEN stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Compugen earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Compugen.

Some companies that are related to Compugen include DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), Cellectis (CLLS), Vericel (VCEL), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST) and MeiraGTx (MGTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), Pluristem Therapeutics (PSTI), Sarepta Therapeutics (SRPT), Catalyst Pharmaceuticals (CPRX), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Novavax (NVAX), REDHILL BIOPHAR/S (RDHL) and AT&T (T).

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $6.17.

Compugen has a market capitalization of $316.46 million and generates $17.80 million in revenue each year. The biotechnology company earns $-22,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.

The official website for Compugen is http://www.cgen.com/.

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]